150 related articles for article (PubMed ID: 37559575)
1. Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report.
Inoue S; Win KHN; Mon CY; Fujikawa T; Hyodo S; Uemura S; Ishida T; Mori T; Hasegawa D; Kosaka Y; Nishimura A; Nakatani N; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
Oncol Lett; 2023 Sep; 26(3):369. PubMed ID: 37559575
[TBL] [Abstract][Full Text] [Related]
2. Minimal Residual Disease Detected by the 7NB-mRNAs ddPCR Assay Is Associated with Disease Progression in High-Risk Neuroblastoma Patients: A Prospective Multicenter Observational Study in Japan.
Nishimura N; Ishida T; Yokota I; Matsumoto K; Shichino H; Fujisaki H; Sarashina T; Kamijo T; Takimoto T; Iehara T; Tajiri T; On Behalf Of The Jccg Neuroblastoma Committee
Biology (Basel); 2023 Oct; 12(10):. PubMed ID: 37887060
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood.
Lin KS; Uemura S; Thwin KKM; Nakatani N; Ishida T; Yamamoto N; Tamura A; Saito A; Mori T; Hasegawa D; Kosaka Y; Nino N; Nagano C; Takafuji S; Iijima K; Nishimura N
Transl Oncol; 2021 Aug; 14(8):101019. PubMed ID: 33993097
[TBL] [Abstract][Full Text] [Related]
4. Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma-associated mRNAs in high-risk neuroblastoma patients.
Uemura S; Lin KS; Mon Thwin KK; Nakatani N; Ishida T; Yamamoto N; Tamura A; Saito A; Mori T; Hasegawa D; Kosaka Y; Nino N; Nagano C; Takafuji S; Iijima K; Nishimura N
Mol Clin Oncol; 2021 Jul; 15(1):137. PubMed ID: 34055352
[TBL] [Abstract][Full Text] [Related]
5. Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients.
Nakatani N; Win KHN; Mon CY; Fujikawa T; Uemura S; Saito A; Ishida T; Mori T; Hasegawa D; Kosaka Y; Inoue S; Nishimura A; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
Biology (Basel); 2024 May; 13(5):. PubMed ID: 38785826
[TBL] [Abstract][Full Text] [Related]
6. Level of Seven Neuroblastoma-Associated mRNAs Detected by Droplet Digital PCR Is Associated with Tumor Relapse/Regrowth of High-Risk Neuroblastoma Patients.
Thwin KKM; Ishida T; Uemura S; Yamamoto N; Lin KS; Tamura A; Kozaki A; Saito A; Kishimoto K; Mori T; Hasegawa D; Kosaka Y; Nino N; Takafuji S; Iijima K; Nishimura N
J Mol Diagn; 2020 Feb; 22(2):236-246. PubMed ID: 31837427
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.
Yamamoto N; Kozaki A; Hartomo TB; Yanai T; Hasegawa D; Kawasaki K; Kosaka Y; Matsuo M; Hirase S; Mori T; Hayakawa A; Iijima K; Nishio H; Nishimura N
Oncol Lett; 2015 Nov; 10(5):3228-3232. PubMed ID: 26722317
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease detected by droplet digital PCR in peripheral blood stem cell grafts has a prognostic impact on high-risk neuroblastoma patients.
Nino N; Ishida T; Nakatani N; Lin KS; Win KHN; Mon CY; Nishimura A; Inoue S; Tamura A; Yamamoto N; Uemura S; Saito A; Mori T; Hasegawa D; Kosaka Y; Nozu K; Nishimura N
Heliyon; 2022 Oct; 8(10):e10978. PubMed ID: 36276741
[TBL] [Abstract][Full Text] [Related]
9. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Yalcin B; Dee R; van Noesel MM; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Clin Chem; 2009 Jul; 55(7):1316-26. PubMed ID: 19460840
[TBL] [Abstract][Full Text] [Related]
10. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
11. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Maurillo L; Buccisano F; Spagnoli A; Del Poeta G; Panetta P; Neri B; Del Principe MI; Mazzone C; Consalvo MI; Tamburini A; Ottaviani L; Fraboni D; Sarlo C; De Fabritiis P; Amadori S; Venditti A
Haematologica; 2007 May; 92(5):605-11. PubMed ID: 17488683
[TBL] [Abstract][Full Text] [Related]
13. RT-PCR demonstrates superior sensitivity and specificity in detecting the five neuroblastoma genes compared to the flow cytometry method for measurable residual disease.
Tian X; Li H; Luo T; Mao J; Yuan X; Gao Q; Xiao J; Qian S; Zou R; Chen K; Zhu C; Yi C; He X
Transl Pediatr; 2023 Dec; 12(12):2232-2246. PubMed ID: 38197110
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of Minimal Residual Disease in Neuroblastoma Patients.
Uemura S; Ishida T; Thwin KKM; Yamamoto N; Tamura A; Kishimoto K; Hasegawa D; Kosaka Y; Nino N; Lin KS; Takafuji S; Mori T; Iijima K; Nishimura N
Front Oncol; 2019; 9():455. PubMed ID: 31214500
[TBL] [Abstract][Full Text] [Related]
16. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
Yáñez Y; Grau E; Oltra S; Cañete A; Martínez F; Orellana C; Noguera R; Palanca S; Castel V
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1263-72. PubMed ID: 21706131
[TBL] [Abstract][Full Text] [Related]
17. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
Juul-Dam KL; Ommen HB; Nyvold CG; Walter C; Vålerhaugen H; Kairisto V; Abrahamsson J; Alm SJ; Jahnukainen K; Lausen B; Reinhardt D; Zeller B; von Neuhoff N; Fogelstrand L; Hasle H
Br J Haematol; 2020 Jul; 190(2):198-208. PubMed ID: 32175599
[TBL] [Abstract][Full Text] [Related]
18. Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients.
Hirase S; Saitoh A; Hartomo TB; Kozaki A; Yanai T; Hasegawa D; Kawasaki K; Kosaka Y; Matsuo M; Yamamoto N; Mori T; Hayakawa A; Iijima K; Nishio H; Nishimura N
Oncol Lett; 2016 Aug; 12(2):1119-1123. PubMed ID: 27446404
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.
Inoue K; Ogawa H; Yamagami T; Soma T; Tani Y; Tatekawa T; Oji Y; Tamaki H; Kyo T; Dohy H; Hiraoka A; Masaoka T; Kishimoto T; Sugiyama H
Blood; 1996 Sep; 88(6):2267-78. PubMed ID: 8822948
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Eur J Cancer; 2011 May; 47(8):1193-202. PubMed ID: 21429738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
